603439.SHG Guizhou Sanli Pharmaceutical Co Ltd

Healthcare Biotechnology Shanghai Stock Exchange
11.26 CNY
Close of Nov 5, 2026
9.51 17.46
Market cap
CNY 4.55B
P/E
86.6x
P/B
2.88x
ROE
7.7%
Dividend yield
3.55%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 603439.SHG undervalued?

Graham number

The Graham number of Guizhou Sanli Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Guizhou Sanli Pharmaceutical Co Ltd fundamental analysis

No fundamental analysis for Guizhou Sanli Pharmaceutical Co Ltd yet.

Guizhou Sanli Pharmaceutical Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Guizhou Sanli Pharmaceutical Co Ltd

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointment…

Full company profile